News|Articles|September 19, 2024

New Pembrolizumab Data Presented at ESMO Show Promise in a Variety of Cancers

Author(s)Aislinn Antrim, Associate Editorial Director

Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy designed to increase the immune system’s ability to detect and fight tumor cells.

Multiple new trial results have been presented at the European Society for Medical Oncology (ESMO) Congress 2024 supporting the use of pembrolizumab (Keytruda; Merck) in a variety of cancer types, including breast cancer, melanoma, hepatocellular carcinoma, and cervical cancer.